Valion Bio (VBIO) Other Accumulated Expenses (2021 - 2026)
Valion Bio (VBIO) posted quarterly Other Accumulated Expenses of $376000.0 for Q4 2025, up 184.85% year-over-year from $132000.0 in Q4 2024, and up 117.34% quarter-over-quarter from $173000.0 in Q3 2025.
Valion Bio (VBIO) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Valion Bio's Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $376000.0 for Q4 2025.
- In Q4 2025, Other Accumulated Expenses rose 184.85% year-over-year to $376000.0; the TTM figure through Dec 2025 stood at $376000.0 (up 184.85% YoY), while the FY2025 annual figure was $376000.0, up 184.85% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $376000.0, up from $173000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $587000.0 in Q2 2025, with the low at $132000.0 in Q4 2024.
- The 5-year median for Other Accumulated Expenses is $267000.0 (2021), against an average of $285294.1.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses slumped 73.33% in 2024, then jumped 304.83% in 2025.
- Valion Bio's Other Accumulated Expenses stood at $267000.0 in 2021, then soared by 46.82% to $392000.0 in 2022, then increased by 26.28% to $495000.0 in 2023, then plunged by 73.33% to $132000.0 in 2024, then soared by 184.85% to $376000.0 in 2025.
- Business Quant data shows VBIO's Other Accumulated Expenses at $376000.0 in Q4 2025, $173000.0 in Q3 2025, and $587000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 173,000.00 |
| Jun 30, 2025 | 587,000.00 |
| Mar 31, 2025 | 303,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Mar 31, 2024 | 265,000.00 |
| Dec 31, 2023 | 495,000.00 |
| Sep 30, 2023 | 189,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Mar 31, 2023 | 297,000.00 |
| Dec 31, 2022 | 392,000.00 |
| Sep 30, 2022 | 261,000.00 |
| Jun 30, 2022 | 293,000.00 |
| Mar 31, 2022 | 304,000.00 |
| Dec 31, 2021 | 267,000.00 |